Question 1

What is Pfizer's P/E ratio?

Accepted Answer

Pfizer (PFE) P/E ratio is 19.0× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Pfizer?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Pfizer specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Pfizer's P/E ratio high or low?

Accepted Answer

Pfizer's P/E ratio of 19.0× is above its own 5-year average of 18.7× and below the sector median of 24.2×. That places the current reading at the 76th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Pfizer's historical P/E ratio range?

Accepted Answer

In the available daily series, Pfizer (PFE) P/E ratio has ranged from a low of 6.9× in 2023 to a high of 160.1× in 2004. The 5-year average is 18.7× and the 5-year median is 13.8×.

Question 7

What was Pfizer's P/E ratio in 2025?

Accepted Answer

Pfizer (PFE) P/E ratio at the end of 2025 was 18.2×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Pfizer's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$142B	$7.77B	18.2×	-0.5×	Dec 31, 2025
2024	$150B	$8.02B	18.7×	-57.4×	Dec 31, 2024
2023	$163B	$2.13B	76.2×	+67.0×	Dec 31, 2023
2022	$288B	$31.4B	9.2×	-5.7×	Dec 31, 2022
2021	$332B	$22.2B	14.9×	-7.4×	Dec 31, 2021
2020	$205B	$9.16B	22.4×	+9.7×	Dec 31, 2020
2019	$206B	$16.3B	12.6×	-8.8×	Dec 31, 2019
2018	$240B	$11.2B	21.5×	+11.9×	Dec 31, 2018
2017	$205B	$21.3B	9.6×	-16.4×	Dec 31, 2017
2016	$187B	$7.18B	26.0×	-1.1×	Dec 31, 2016
2015	$189B	$6.96B	27.1×	+6.8×	Dec 31, 2015
2014	$186B	$9.13B	20.4×	+11.9×	Dec 31, 2014
2013	$187B	$22B	8.5×	-3.4×	Dec 31, 2013
2012	$174B	$14.6B	11.9×	-3.7×	Dec 31, 2012
2011	$157B	$10B	15.6×	-0.5×	Dec 31, 2011
2010	$133B	$8.26B	16.1×	+2.6×	Dec 31, 2010
2009	$117B	$8.64B	13.5×	-0.4×	Dec 31, 2009
2008	$113B	$8.1B	13.9×	-4.0×	Dec 31, 2008
2007	$146B	$8.14B	17.9×	+8.9×	Dec 31, 2007
2006	$175B	$19.3B	9.1×	-11.0×	Dec 31, 2006
2005	$162B	$8.08B	20.0×	+3.3×	Dec 31, 2005
2004	$190B	$11.4B	16.7×	-48.3×	Dec 31, 2004
2003	$254B	$3.91B	65.0×	+45.6×	Dec 31, 2003
2002	$177B	$9.13B	19.4×	—	Dec 31, 2002


Agilent Technologies (A)	23.1×
Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Pfizer (PFE) 2002-2026

P/E Ratio daily chart for Pfizer (PFE)

Historical P/E Ratio for Pfizer (PFE) from 2002 to 2025

About P/E Ratio at Pfizer (PFE)

Pfizer P/E Ratio by Year

Pfizer P/E Ratio 2025: 18.2×

Pfizer P/E Ratio 2024: 18.7×

Pfizer P/E Ratio 2023: 76.2×

Pfizer P/E Ratio 2022: 9.2×

Pfizer P/E Ratio 2021: 14.9×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Pfizer (PFE) Key Financials